(2R)-2-acetamido-3-sulfanylpropanoic acid;5-(dithiolan-3-yl)pentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-acetamido-3-sulfanylpropanoic acid;5-(dithiolan-3-yl)pentanoic acid
• 化学式: C13H23NO5S3
• 分子量: 369.5
• InChiKey: ODIQEOLTSZIQNY-VWMHFEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.29
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• LOW MOLECULAR WEIGHT PHARMACOLOGICAL ACTIVITY MODULATORS
  申请人："Ivy Pharm" Jsc.

  公开号：EP2455386A1

  公开（公告）日：2012-05-23

  (57) Abstract: Claimed are a compound of the general formula (I) and pharmaceutically acceptable salts thereof, where M signifies metal atoms selected independently from the group comprising Pd, Fe, Mn, Co, Ni, Cu, Zn and Mo; R1 and R2, independently of each other, signify hydrogen, amino, hydroxy, oxy, carboxy, cyano, C1-12alkyl, C2-12alkenyl, C2-12alkynyl, C1-12alkoxy, C1-12alkylamino, C1-12alkoxycarbonyl, C1-2alkylamido, arylamido, wherein the alkylene groupings in the given substituents can in turn be substituted by one or more of the following groups: hydroxy, oxy, carboxy, amino or amido; R3-R10, independently of each other, signify hydrogen; or NHR3R4 and NHR5R6, taken together, and/or NHR7R8 and NHR9R10, taken together, are a ligand (or ligands) containing one or several donor aliphatic or aromatic atoms of nitrogen and being in cis position on the metal atoms (M). The claimed compound can be used in a preparation containing a coordination compound and free molecules of an aliphatic thiol (or derivatives thereof), which are not bound to the coordination compound. The coordination compound and the free molecules of an aliphatic thiol (or derivatives thereof) in the preparation can be in either cationic or anionic form or in the form of neutral particles. The proposed substances are capable of making the action of drugs more effective by increasing the affinity of the target to the drug and/or providing for therapeutically optimal concentrations of the drug in the microenvironment of the target and/or reducing the toxicity of drugs.

  (57) 摘要：所要求的是通式（I）化合物及其药学上可接受的盐，其中 M 表示独立选自包括 Pd、Fe、Mn、Co、Ni、Cu、Zn 和 Mo 在内的金属原子；R1 和 R2 相互独立地表示氢、氨基、羟基、氧基、羧基、氰基、C1-12 烷基、C2-12 烯基、C2-12炔基、C1-12 烷氧基、C1-12 烷基氨基、C1-12 烷氧基羰基、C1-2 烷基氨基、芳基氨基，其中给定取代基中的亚烷基可依次被以下一个或多个基团取代：羟基、氧基、羧基、氨基或酰胺基；R3-R10 相互独立地表示氢；或 NHR3R4 和 NHR5R6 合在一起，和/或 NHR7R8 和 NHR9R10 合在一起，是含有一个或多个供体脂肪族或芳香族氮原子且在金属原子（M）上处于顺式位置的配体（或配位体）。所述化合物可用于含有配位化合物和未与配位化合物结合的脂肪族硫醇（或其衍生物）游离分子的制剂中。配位化合物和制剂中脂肪族硫醇（或其衍生物）的游离分子可以是阳离子或阴离子形式，也可以是中性颗粒形式。所提议的物质能够通过增加靶点对药物的亲和力和/或在靶点的微环境中提供治疗上最佳的药物浓度和/或降低药物的毒性，使药物的作用更加有效。
• US8575382B2
  申请人：——

  公开号：US8575382B2

  公开（公告）日：2013-11-05